Immunotherapy Combinations for Cancer

Recruiting at 48 trial locations

Overseen By BMS Study Connect Contact Center www.BMSStudyConnect.com

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Bristol-Myers Squibb

Disqualifiers: CNS metastases, Pneumonitis, Active malignancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

229 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.

Research Team

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Eligibility Criteria

This trial is for adults with certain advanced solid cancers that have spread and can't be removed by surgery. Participants should be relatively healthy (ECOG status of 0 or 1) and have a tumor that can be measured. They must also provide tissue samples for research. People with brain metastases, lung inflammation history, active cancer in the last two years (except some skin cancers), or recent serious neurological issues cannot join.

Inclusion Criteria

I have tumor tissue available for testing.

I am fully active or can carry out light work.

My cancer is advanced, cannot be surgically removed, and its size can be measured.

Exclusion Criteria

I have had lung inflammation or scarring before.

I haven't had any cancer except for treated skin cancer in the last 2 years.

My cancer has spread to my brain or is only active there.

Treatment Details

Interventions

• BMS-986205
• Ipilimumab
• Nivolumab
• Relatlimab

Trial Overview The study tests combinations of immunotherapy drugs: relatlimab with nivolumab and BMS-986205, or relatlimab with nivolumab and ipilimumab. It aims to find out how safe these combinations are and how well they work against different types of advanced tumors in patients who haven't had immunotherapy before as well as those who have.

Participant Groups

Group I: Arm B Experimental Treatment 3 Interventions

Relatlimab + Nivolumab + Ipilimumab

Group II: Arm A Experimental Treatment 3 Interventions

Relatlimab + Nivolumab + BMS-986205

Who Is Running the Clinical Trial?

Bristol-Myers Squibb

Lead Sponsor

Trials

2,731

Recruited

4,127,000+

Headquarters

New York City, USA

Known For

Oncology & Cardiovascular

Top Products

Eliquis, Opdivo, Revlimid, Orencia

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis

Deepak L. Bhatt

Bristol-Myers Squibb

Chief Medical Officer since 2024

MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania